Journal
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
Volume 9, Issue 5, Pages 455-467Publisher
TAYLOR & FRANCIS AS
DOI: 10.1586/ERM.09.25
Keywords
breast cancer; microarray; microRNA; molecular diagnostics; predictive value; prognostic value
Categories
Funding
- NATIONAL CANCER INSTITUTE [ZIABC010729, ZIASC010437] Funding Source: NIH RePORTER
- Intramural NIH HHS [Z99 CA999999] Funding Source: Medline
Ask authors/readers for more resources
Although comprehensive molecular diagnostics and personalized medicine have sparked excitement among researchers and clinicians, they have yet to be fully incorporated into today's standard of care. This is despite the discovery of disease-related oncogenes, tumor-suppressor genes and protein biomarkers, as well as other biological anomalies related to cancer. Each year, new tests are released that could potentially supplement or surpass standard methods of diagnosis, including serum, protein and gene expression analyses. All of these novel approaches have shown great promise, but initial enthusiasm has diminished as difficulties in reproducibility, expense, standardization and proof of significance beyond current protocols have emerged. This review will focus on current and novel molecular diagnostic tools applied to breast cancer with special attention to the exciting new field of microRNA analysis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available